Skip to main content

Table 12 P values for change in MDA levels within the groups (from baseline to the end of the treatment period) and between the groups

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Statistics

4 weeks

12 weeks

24 weeks

A

p ≤ 0.0001

p ≤ 0.0001

p ≤ 0.0001

B

p ≤ 0.05

p ≤ 0.0001

p ≤ 0.0001

C

p ≤ 0.0001

p ≤ 0.0001

p ≤ 0.0001

A vs B

p ≤ 0.001

p ≤ 0.001

p ≤ 0.001

A vs C

p ≤ 0.05

p ≤ 0.01

p ≤ 0.001

C vs B

ns

ns

ns

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us